Subanesthetic ketamine for cancer pain: by insisting on level I/II evidence, do we risk throwing the baby out with the bath water?
Jackson
Kate
K
Ashby
Michael
M
Goodchild
Colin
C
D000328:Adult; D000700:Analgesics / Q000008:administration & dosage; D000778:Anesthetics, Dissociative / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D019317:Evidence-Based Medicine; D005260:Female; D005266:Femoral Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D007649:Ketamine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology*; D010166:Palliative Care / Q000379:methods*; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D013727:Terminal Care / Q000379:methods*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000401:mortality
D000700:Analgesics; D000778:Anesthetics, Dissociative; D007649:Ketamine